top of page
We work on the immunology, vaccinology, and host defense against highly resistant infections, including those caused by Acinetobacter, carbapenem-resistant Enterobacteriaceae, and S. aureus. We have an active discovery and development program for monoclonal antibodies targeting A. baumannii. We have a very exciting translational program using a patented combinationof vaccine adjuvants which protects against infection caused by many highly resistant nosocomial pathogens, and is promising as a novel means to prevent hospital acquired infections. The over-arching theme of our lab work is to understand how pathogens interface with host response to cause disease, with an intent to develop immune-modulatory therapeutic interventions to improve morbidity and mortality of these infections.
bottom of page